Asset
Tradipitant
Vanda Pharmaceuticals Inc. Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (17)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT07446439 | phase3 | recruiting | 2026-03-27 | 2026-12-01 | Vanda Pharmaceuticals | A Study to Evaluate Tradipitant on Treating Nausea and Vomiting Induced by GLP-1R Agonist Use |
| NCT06804603 | phase2 | completed | 2025-02-25 | 2025-10-06 | Vanda Pharmaceuticals | A Study to Measure the Effects of Using Tradipitant on Nausea and Vomiting After GLP-1R Agonist Use |
| NCT04849559 | phase1_2 | completed | 2021-02-01 | 2021-09-24 | Vanda Pharmaceuticals | Effects of Tradipitant on Satiation, Gastric Volume, Gastric Accommodation, and Gastric Emptying in Healthy Volunteers |
| NCT03568331 | phase3 | completed | 2018-07-09 | 2019-12-27 | Vanda Pharmaceuticals | Evaluating the Effects of Tradipitant vs. Placebo in Atopic Dermatitis (EPIONE) |
| NCT04140695 | phase3 | terminated | 2019-10-21 | 2020-10-14 | Vanda Pharmaceuticals | Evaluating the Effects of Tradipitant vs. Placebo in Atopic Dermatitis (EPIONE2) |
FDA applications (1)
| Application | Type | Applicant |
|---|---|---|
| NDA 220152 | NDA | VANDA PHARMACEUTICALS INC |
Marketed products (1)
- NEREUS